
Does six-monthly PrEP have a future following the collapse of global HIV funding?
“Lenacapavir is a product with real transformational potential that has the power to change the history of HIV,” Carolyn Amole of the Clinton Health Access Initiative (CHAI) told last week’s 13th International AIDS Society Conference on HIV Science (IAS …